Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.785 USD | -5.52% | -0.42% | -1.21% |
Mar. 12 | Outlook Therapeutics to Begin Reverse Stock Split for Regaining Nasdaq Compliance | MT |
Feb. 16 | North American Morning Briefing : S&P 500 Seen -2- | DJ |
Financials (USD)
Sales 2024 * | 204K | Sales 2025 * | 11.9M | Capitalization | 107M |
---|---|---|---|---|---|
Net income 2024 * | -70M | Net income 2025 * | -62M | EV / Sales 2024 * | 526 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 9.01 x |
P/E ratio 2024 * |
-2.11
x | P/E ratio 2025 * |
-3.07
x | Employees | 24 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 56.65% |
Latest transcript on Outlook Therapeutics, Inc.
1 day | -5.52% | ||
1 week | -1.51% | ||
Current month | -10.89% | ||
1 month | -13.81% | ||
3 months | +1.45% | ||
6 months | +80.96% | ||
Current year | -1.21% |
Managers | Title | Age | Since |
---|---|---|---|
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Lawrence Kenyon
DFI | Director of Finance/CFO | 58 | 15-09-14 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 23-01-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randy Thurman
CHM | Chairman | 74 | 18-04-12 |
Kurt Hilzinger
BRD | Director/Board Member | 63 | 15-12-10 |
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 8 M€ | +6.48% | - | |
0.00% | 142 M€ | +4.49% | - | |
0.00% | 17 M€ | +4.72% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 7.785 | -5.52% | 419,302 |
24-03-15 | 8.24 | +43.80% | 2,273,699 |
24-03-14 | 5.73 | -11.33% | 570,024 |
24-03-13 | 6.462 | -7.58% | 180,019 |
24-03-12 | 6.992 | -10.57% | 219,925 |
Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.21% | 107M | |
+9.72% | 46B | |
+35.14% | 39.85B | |
+4.84% | 39.76B | |
-9.43% | 28.16B | |
+17.47% | 27.62B | |
-22.99% | 18.8B | |
+10.88% | 13.3B | |
+27.53% | 12.2B | |
-6.84% | 11.4B |